Updated Jul 16, 2026
Lee Chan Henry has filed 5 SEC Form 4 filings across 1 company in the last 90 days — selling. Lifetime open-market sales: $12.46M.
Chan Henry Lee serves as the Senior Vice President and General Counsel at BeOne Medicines Ltd., a biotechnology company focused on oncology therapeutics. He has been involved in the company since its listing on the Hong Kong exchange in 2018.
| Role | SVP, General Counsel |
|---|---|
| Notability | 20/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-07-10 | ONC | BeOne Medicines Ltd. | S — Open-market sale | 664 | $302.46 | $201K |
| 2026-07-10 | ONC | BeOne Medicines Ltd. | M — Option exercise | 196 | $159.03 | $31K |
| 2026-07-10 | ONC | BeOne Medicines Ltd. | M — Option exercise | 266 | $213.32 | $57K |
| 2026-07-10 | ONC | BeOne Medicines Ltd. | M — Option exercise | 202 | $194.47 | $39K |
| 2026-06-18 | ONC | BeOne Medicines Ltd. | S — Open-market sale | 590 | $265.98 | $157K |
| 2026-06-15 | ONC | BeOne Medicines Ltd. | S — Open-market sale | 428 | $257.63 | $110K |
| 2026-06-15 | ONC | BeOne Medicines Ltd. | A — Grant or award | 45.1K | $0.00 | |
| 2026-06-10 | ONC | BeOne Medicines Ltd. | S — Open-market sale | 160 | $271.26 | $43K |
| 2026-06-10 | ONC | BeOne Medicines Ltd. | S — Open-market sale | 711 | $270.24 | $192K |
| 2026-05-15 | ONC | BeOne Medicines Ltd. | S — Open-market sale | 332 | $310.72 | $103K |
| 2026-05-15 | ONC | BeOne Medicines Ltd. | M — Option exercise | 98 | $159.03 | $16K |
| 2026-05-15 | ONC | BeOne Medicines Ltd. | M — Option exercise | 133 | $213.32 | $28K |
| 2026-05-15 | ONC | BeOne Medicines Ltd. | M — Option exercise | 101 | $194.47 | $20K |
| 2026-04-10 | ONC | BeOne Medicines Ltd. | S — Open-market sale [10b5-1] | 332 | $311.59 | $103K |
| 2026-04-10 | ONC | BeOne Medicines Ltd. | M — Option exercise [10b5-1] | 98 | $159.03 | $16K |
| 2026-04-10 | ONC | BeOne Medicines Ltd. | M — Option exercise [10b5-1] | 133 | $213.32 | $28K |
| 2026-04-10 | ONC | BeOne Medicines Ltd. | M — Option exercise [10b5-1] | 101 | $194.47 | $20K |
| 2026-03-13 | ONC | BeOne Medicines Ltd. | S — Open-market sale [10b5-1] | 341 | $300.00 | $102K |
| 2026-03-13 | ONC | BeOne Medicines Ltd. | M — Option exercise [10b5-1] | 98 | $159.03 | $16K |
| 2026-03-13 | ONC | BeOne Medicines Ltd. | M — Option exercise [10b5-1] | 133 | $213.32 | $28K |
Chan Henry Lee serves as the Senior Vice President and General Counsel at BeOne Medicines Ltd., a biotechnology company focused on oncology therapeutics. He has been involved in the company since its listing on the Hong Kong exchange in 2018.…
5 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 24 open-market sales ($12.46M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Lee Chan Henry profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.